IL23R and psoriasis: Therapeutic applications that mimic this effect (i.e., reduction of IL-23R by neutralisation of IL-23) lead to significantly lower levels of inflammation with breakthrough clinical efficacy levels in psoriasis, CD and UC.20, 21, 22, 23, 24, 25, 26 It is highly surprising that the high efficacy of such significant interventions is associated with only minor side-effects.